Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments. Jubilant Therapeutics Inc. is developing a novel small molecule PAD4 inhibitor that directly targets this mechanism. The findings appear in Cancer Research.
You may also be interested in:
Researchers are joining forces with the food and health industries to tighten controls and improve nutrition for infants and children.This article was originally published on [...]
Toddlers whose moms were exposed to higher levels of air pollution during mid- to late-pregnancy tend to score lower on measures of cognition, motor coordination [...]
When visiting friends or family who have both houseplants and young children, I’ve been compared to “Aunt Bonnie” from the Geico commercial “Aunt Infestation.”This article [...]